BIOLIFE SOLUTIONS (NASDAQ:BLFS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 of the Original Form 8-K to disclose the decision of the Board of Directors of the Company (the \”Board of Directors\”) with respect to the frequency of future stockholder advisory votes on the compensation of the Company\’s named executive officers. Stockholder proposals for the Company’s 2020 Annual Meeting of Stockholders, along with proof of ownership of the Company’s common stock in accordance with Rule 14a-8(b)(2), must be received by the Company not later than Wednesday, January 20, 2020.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the Annual Meeting, the Company\’s stockholders voted on, among other matters, an advisory proposal concerning the frequency of holding future stockholder advisory votes to approve, on an advisory basis, the compensation of the Company\’s named executive officers. As previously reported in the Original Form 8-K, the results of the voting were as follows:
Approval, by non-binding advisory vote, on the frequency of advisory votes on the Company’s executive compensation
The frequency of one year for future advisory votes on the Company’s executive compensation was approved by non-binding advisory vote. The voting results were as follows:
In light of the stockholders\’ vote that the advisory vote be held every year, the Board of Directors has decided that the Company will hold an annual stockholder advisory vote to approve, on an advisory basis, the compensation of the Company\’s named executive officers. The Company intends to continue holding such votes annually until the next required vote on the frequency of the stockholder advisory vote on named executive officer compensation.
About BIOLIFE SOLUTIONS (NASDAQ:BLFS)
BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.
